VivoSeq
Oncology

Metastatic Nasopharyngeal Cancer

0

Pipeline Programs↗

1

Active Trials↗

6

Companies Involved↗

Metastatic Nasopharyngeal Cancer is an early-stage landscape with 0 programs across 6 companies. The most active players are Roche, Eastern Cooperative Oncology Group, Coherus Oncology, Inc..

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

78/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

0 programs

PreclinicalE

Eastern Cooperative Oncology Group

0 programs

PreclinicalC

Coherus Oncology, Inc.

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalBeiGene logo

BeiGene

0 programs

PreclinicalChia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

12

clinical trials

Completed7 · 58%
Terminated2 · 17%
Unknown status2 · 17%
Recruiting1 · 8%

Clinical Trials

Trial Activity

12 trials

A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
Recruiting·CCoherus Oncology, Inc.·Phase 4·NCT06457503·100 enrolled
A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer
Completed·Roche logoRoche·Phase 2·NCT02608073·45 enrolled
Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer
Completed·National Cancer Institute (NCI)·Phase 2·NCT00305734·50 enrolled
Carboplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer
Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003206
A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.
Completed·Roche logoRoche·Phase 2·NCT00439426·25 enrolled
Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer
Completed·National Cancer Institute (NCI)·Phase 2·NCT02339558·45 enrolled
Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT02611960·233 enrolled
Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)
Completed·BeiGene logoBeiGene·Phase 3·NCT03924986·263 enrolled
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
Terminated·National Cancer Institute (NCI)·Phase 3·NCT04458909·15 enrolled
Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer
Terminated·—·Phase 2·NCT02875613·6 enrolled
Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer
Unknown status·National Cancer Centre, Singapore·Phase 2·NCT00589186·35 enrolled
To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer
Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logoChia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1/2·NCT05198531·90 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)